ESMO : Vienna 2012 Congress . 1-October 2012 .
... In conclusion, Lurbinectedin ( PM 01183 ) showed promise in patients with Platinum-Resistant/Refractory Ovarian Cancer and is now being evaluated against comparator therapy with Topotecan. According to Dr. Cristiana Sessa next steps in the Clinical development of this drug would be testing of Combination with Chemotherapy ( Platinum ).
The results merit further investigation in Ovarian cancer and Pancreatic Adenocarcinoma. Until then additional data are needed, especially comparison with Trabectedin ( Yondelis ) with or without Cisplatin in Ovarian Xenografts, Confirmation of pre-clinical results in Resistant Epithelial Ovarian Cancer and Evaluation in Pharmacokinetic differences with Trabectedin.